| Outcome Measures: |
Primary: Change in glycated haemoglobin (HbA1c), percent-points, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|Number of adverse event (AEs), Count, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44) | Secondary: Relative change in body weight, percent, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|Absolute change in body weight, Kilogram (Kg), From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|HbA1c less than 7 percent (Yes/No), Percentage of patients achieving or not achieving the target value, End of Study visit (Visit 3) (week 34-44)|HbA1c reduction greater than or equal to 1 percent-points and body weight reduction of greater than or equal to 5 percent (Yes/No), Percentage of patients achieving or not achieving the target value, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|HbA1c reduction greater than or equal to 1 percent-points and body weight reduction of greater than or equal to 3 percent (Yes/No), Percentage of patients achieving or not achieving the target value, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|Number of adverse reactions (ARs), Count, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)|Number of serious adverse events (SAEs), Count, From baseline (week 0) to End of Study visit (Visit3) (week 34-44)|Number of serious adverse reactions (SARs), Count, From baseline (week 0) to End of Study visit (Visit 3) (week 34-44)
|
